Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Immutep Ltd ( (AU:IMM) ) is now available.
Immutep Limited has entered into a strategic collaboration with Dr. Reddy’s Laboratories for the commercialization of its innovative oncology drug, Eftilagimod Alfa, outside North America, Europe, Japan, and Greater China. This agreement grants Dr. Reddy’s exclusive rights to develop and commercialize the drug in these regions, while Immutep retains manufacturing rights globally and rights in key markets. The collaboration includes an upfront payment of USD 20 million to Immutep, with potential milestone payments and royalties. This partnership is expected to enhance Immutep’s market presence and leverage Dr. Reddy’s capabilities to maximize the drug’s impact, potentially setting a new standard in cancer treatment.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), aiming to harness its potential to stimulate or suppress immune responses. Immutep is committed to providing innovative treatment options and maximizing value for its shareholders.
YTD Price Performance: -28.77%
Average Trading Volume: 2,326,586
Technical Sentiment Signal: Sell
Current Market Cap: A$382.7M
For an in-depth examination of IMM stock, go to TipRanks’ Overview page.